Financials in USD. Standardized financial statements.
A compact view of how China Shineway Pharmaceutical Group Limited turns revenue into operating income and net income.
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue? | $3.05B | $3.78B | $4.52B | $4.02B | $3.18B | $2.66B | $2.71B | $2.57B | $1.92B | $2.09B |
| Revenue Growth? | -19.3% | -16.4% | +12.4% | +26.3% | +19.8% | -1.9% | +5.3% | +33.9% | -7.9% | 0.0% |
| Cost of Revenue? | $845.53M | $946.29M | $1.12B | $1.01B | $813.21M | $667.86M | $724.43M | $694.15M | $652.52M | $706.88M |
| Gross Profit? | $2.20B | $2.83B | $3.39B | $2.94B | $2.41B | $1.99B | $1.98B | $1.88B | $1.27B | $1.29B |
| Gross Margin? | +72.3% | +75.0% | +75.1% | +73.1% | +75.8% | +74.9% | +73.2% | +73.0% | +66.0% | +61.7% |
| Operating Expenses? | $1.54B | $1.99B | $2.42B | $2.22B | $1.85B | $1.48B | $1.51B | $1.34B | $836.88M | $754.86M |
| Operating Income? | $663.48M | $842.60M | $975.53M | $726.11M | $527.45M | $399.34M | $476.48M | $494.30M | $398.33M | $590.84M |
| EBITDA? | $732.44M | $1.22B | $1.42B | $1.10B | $903.74M | $620.04M | $850.41M | $557.82M | $442.54M | $778.67M |
| Income Before Tax | $1.23B | $1.15B | $1.24B | $933.13M | $710.78M | $373.46M | $642.77M | $669.13M | $573.04M | $727.25M |
| Income Tax Expense | $310.62M | $305.67M | $270.74M | $194.25M | $163.43M | $99.99M | $139.62M | $163.25M | $136.27M | $106.06M |
| Net Income? | $924.07M | $840.05M | $969.51M | $722.77M | $556.67M | $295.03M | $503.15M | $505.88M | $451.55M | $589.20M |
| EPS? | $489.40 | $444.00 | $512.20 | $384.00 | $296.00 | $156.00 | $257.80 | $248.00 | $220.00 | $284.00 |
| Diluted EPS? | $489.40 | $444.00 | $513.40 | $384.00 | $296.00 | $156.00 | $256.00 | $248.00 | $220.00 | $284.00 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality